{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:39:31Z","timestamp":1684471171811},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,7,16]],"date-time":"2012-07-16T00:00:00Z","timestamp":1342396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1038\/aps.2012.65","type":"journal-article","created":{"date-parts":[[2012,7,16]],"date-time":"2012-07-16T08:57:36Z","timestamp":1342429056000},"page":"1085-1094","source":"Crossref","is-referenced-by-count":0,"title":["Tolerability, pharmacokinetics and pharmacodynamics of CMAB001, an anti-CD11a antibody, in Chinese healthy volunteers and psoriatic patients"],"prefix":"10.1038","volume":"33","author":[{"given":"Xian-ping","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-zhu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,16]]},"reference":[{"key":"BFaps201265_CR1","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1073\/pnas.0810844106","volume":"106","author":"S Li","year":"2009","unstructured":"Li S, Wang H, Peng B, Zhang M, Zhang D, Hou S, et al. Efalizumab binding to the LFA-1 \u03b1L I domain blocks ICAM-1 binding via steric hindrance. Proc Natl Acad Sci U S A 2009; 106: 4349\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFaps201265_CR2","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S0190-9622(03)01134-4","volume":"49","author":"SL Mehlis","year":"2003","unstructured":"Mehlis SL, Gordon KB . The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003; 49: S44\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"BFaps201265_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000077660","volume":"208","author":"D Jullien","year":"2004","unstructured":"Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004; 208: 297\u2013306.","journal-title":"Dermatology"},{"key":"BFaps201265_CR4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1126\/science.1086507","volume":"302","author":"KH Lee","year":"2003","unstructured":"Lee KH, Dinner AR, Tu C, Campi G, Raychaudhuri S, Varma R, et al. The immunological synapse balances T cell receptor signaling and degradation. Science 2003; 302: 1218\u201322.","journal-title":"Science"},{"key":"BFaps201265_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0190-9622(00)90214-7","volume":"42","author":"A Gottlieb","year":"2000","unstructured":"Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000; 42: 428\u201335.","journal-title":"J Am Acad Dermatol"},{"key":"BFaps201265_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1067\/mjd.2001.117850","volume":"45","author":"K Papp","year":"2001","unstructured":"Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45: 665\u201374.","journal-title":"J Am Acad Dermatol"},{"key":"BFaps201265_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1517\/14712598.3.1.85","volume":"3","author":"RL Dedrick","year":"2003","unstructured":"Dedrick RL, Bodary S, Garovoy MR . Adhesion molecules as therapeutic targets to autoimmune diseases and transplant refection. Expert Opin Biol Ther 2003; 3: 85\u201395.","journal-title":"Expert Opin Biol Ther"},{"key":"BFaps201265_CR8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/0091270004270260","volume":"45","author":"DL Mortensen","year":"2005","unstructured":"Mortensen DL, Walicke PA, Wang X, Kwon P, Kuebler P, Gottlieb AB, et al. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol 2005; 45: 286\u201398.","journal-title":"J Clin Pharmacol"},{"key":"BFaps201265_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1001\/archderm.138.5.591","volume":"138","author":"AB Gottlieb","year":"2002","unstructured":"Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M . Psoriasis as a model for T cell-mediated disease: immunobiologic and clinical effects with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002; 138: 591\u2013600.","journal-title":"Arch Dermatol"},{"key":"BFaps201265_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0966-3274(02)00029-1","volume":"9","author":"RL Dedrick","year":"2002","unstructured":"Dedrick RL, Walicke P, Garovoy M . Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl Immunol 2002; 9: 181\u20136.","journal-title":"Transpl Immunol"},{"key":"BFaps201265_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/archderm.138.5.657","volume":"138","author":"P Singri","year":"2002","unstructured":"Singri P, West DP, Gordon KB . Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002; 138: 657\u201363.","journal-title":"Arch Dermatol"},{"key":"BFaps201265_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/120347540300700607","volume":"7","author":"AB Gottlieb","year":"2003","unstructured":"Gottlieb AB, Miller B, Lowe N, Shapiro W, Hudson C, Bright R, et al. Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cutan Med Surg 2003; 7: 198\u2013207.","journal-title":"J Cutan Med Surg"},{"key":"BFaps201265_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/346425a0","volume":"346","author":"TA Springer","year":"1990","unstructured":"Springer TA . Adhesion receptors of the immune system. Nature 1990; 346: 425\u201334.","journal-title":"Nature"},{"key":"BFaps201265_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/0923-2494(89)90114-4","volume":"140","author":"TW Kuypers","year":"1989","unstructured":"Kuypers TW, Roos D . Leukocyte membrane adhesion proteins LFA-1, CR3 and p150, 95: a review of functional and regulatory aspects. Res Immunol 1989; 140: 461\u201386.","journal-title":"Res Immunol"},{"key":"BFaps201265_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0165-5728(95)00120-2","volume":"62","author":"EJ Gordon","year":"1995","unstructured":"Gordon EJ, Myers KJ, Dougherty JP, Rosen H, Ron Y . Both efalizumab (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 1995; 62: 153\u201360.","journal-title":"J Neuroimmunol"},{"key":"BFaps201265_CR16","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1124\/jpet.104.067611","volume":"310","author":"GP Coffey","year":"2004","unstructured":"Coffey GP, Stefanich E, Palmieri S, Eckert R, Padilla-Eagar J, Fielder PJ, et al. In vitro internalization, intercellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J Pharmacol Exp Ther 2004; 310: 896\u2013904.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFaps201265_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.4161\/mabs.1.6.9884","volume":"1","author":"JR Berger","year":"2009","unstructured":"Berger JR, Houff SA, Major EO . Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs 2009; 1: 583\u20139.","journal-title":"MAbs"},{"key":"BFaps201265_CR18","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1007\/s10620-010-1525-6","volume":"56","author":"DG James","year":"2011","unstructured":"James DG, Seo DH, Chen J, Vemulapalli C, Stone CD . Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn's disease: An open-label pilot study. Dig Dis Sci 2011; 56: 1806\u201310.","journal-title":"Dig Dis Sci"},{"key":"BFaps201265_CR19","unstructured":"Homepage of the Food and Drug Administration. Available from: \n                    http:\/\/www.fda.gov\/ohrms\/ac\/03\/briefing\/3983B1_01_Genentech-Raptiva.pdf\n                    \n                  ."},{"key":"BFaps201265_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1124\/dmd.104.002584","volume":"33","author":"GP Coffey","year":"2005","unstructured":"Coffey GP, Fox JA, Pippig S, Palmieri S, Reitz B, Gonzales M, et al. Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 2005; 33: 623\u20139.","journal-title":"Drug Metab Dispos"},{"key":"BFaps201265_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00403-007-0819-9","volume":"300","author":"AM Langewouters","year":"2008","unstructured":"Langewouters AM, van Erp PE, de Jong EM, van de Kerkhof PC . Lymphocyte subsets in peripheral blood of patients with moderate-to-severe versus mild plaque psoriasis. Arch Dermatol Res 2008; 300: 107\u201313.","journal-title":"Arch Dermatol Res"},{"key":"BFaps201265_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/0091270005283282","volume":"46","author":"A Joshi","year":"2006","unstructured":"Joshi A, Bauer R, Kuebler P, White M, Leddy C, Comptom P, et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody appoved for use in psoriasis. J Clin Pharmacol 2006; 46: 10\u201320.","journal-title":"J Clin Pharmacol"},{"key":"BFaps201265_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.clim.2004.06.001","volume":"113","author":"Y Vugmeyster","year":"2004","unstructured":"Vugmeyster Y, Kikuchi T, Lowes MA, Chamian F, Kagen M, Gilleaudeau P, et al. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol 2004; 113: 38\u201346.","journal-title":"Clin Immunol"},{"key":"BFaps201265_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10227-006-0101-3","volume":"9","author":"NH Shear","year":"2006","unstructured":"Shear NH, Langley RG, Ho V . Efalizumab, a reversible T-cell modulator for psoriasis. J Cutan Med Surg 2006; 9: 4\u20139.","journal-title":"J Cutan Med Surg"},{"key":"BFaps201265_CR25","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/sj.jid.5701169","volume":"128","author":"EG Harper","year":"2008","unstructured":"Harper EG, Simpson EL, Takiquchi RH, Boyd MD, Kurtz SE, Bakke AC, et al. Efalizumab therapy for Atopic Dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen. J Invest Dermatol 2008; 128: 1173\u201381.","journal-title":"J Invest Dermatol"},{"key":"BFaps201265_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1067\/mjd.2002.120568","volume":"46","author":"JG Krueger","year":"2002","unstructured":"Krueger JG . The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1\u201323.","journal-title":"J Am Acad Dermatol"},{"key":"BFaps201265_CR27","first-page":"623","volume":"16","author":"B Bonnekoh","year":"2006","unstructured":"Bonnekoh B, Malykh Y, Bockelmann R, Bartsch S, Pommer AJ, Gollnick H . Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy. Eur J Dermatol 2006; 16: 623\u201335.","journal-title":"Eur J Dermatol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps201265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201265","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:28:33Z","timestamp":1684412913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps201265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,16]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["BFaps201265"],"URL":"https:\/\/doi.org\/10.1038\/aps.2012.65","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,16]]}}}